Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

MiMedx receives notification of Class III certification for HydroFix technology

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has received notification of the Class III certification for a European product using the Company's proprietary HydroFix technology.

24 Dec 2010

InfraReDx to receive $862,000 as part of MLSC Tax Incentive Program

InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has been selected to receive an award of nearly $862,000 as part of the Massachusetts Life Sciences Center Tax Incentive Program. In conjunction with the award, InfraReDx has committed to create 32 new jobs during 2011.

24 Dec 2010

Bonovo Orthopedics announces closing of $10M Series C Preferred Stock financing

Bonovo Orthopedics, Inc., a leading provider of orthopedic products to the Chinese healthcare market, announced today that it closed a US$10 million Series C Preferred Stock financing. The financing was led by OrbiMed Asia Partners and was participated in by Legend Capital and Bonovo's existing shareholders.

24 Dec 2010

Medicago completes first part of H5N1 vaccine Phase II trial

Medicago, a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that the last dose of vaccine has been administered completing the first part of the Company's Phase II human clinical trial with its H5N1 Avian Influenza vaccine.

23 Dec 2010

FDA joins Abbott Diabetes Careto to recall 359 glucose test strips

The test strips being recalled may give falsely low blood glucose results. False results may lead patients to try to raise their blood glucose unnecessarily, or they may fail to treat elevated blood glucose because of a false, low reading. Both scenarios pose risks to a patient's health.

22 Dec 2010

Amorcyte reports AMR-001 phase I trial results in heart attack patients

The American Heart Journal today reported results of a clinical trial evaluating Amorcyte, lead product candidate, AMR-001 for the treatment of damaged heart muscle following acute myocardial infarction.

22 Dec 2010

Mesa Labs announces acquisition of Apex's biological indicators business

Mesa Laboratories, Inc., a Lakewood, Colorado based manufacturer of electronic instruments and disposables today announced the acquisition of the biological indicators business of Apex Laboratories, Inc., a North Carolina based company. The acquisition of the Apex business is expected to be immediately accretive to Mesa's earnings per share.

22 Dec 2010

Tap water cancer chemical detected

A new analysis has revealed a potential carcinogen in the tap water of 31 U.S. cities and experts are looking for ways to reduce exposure of the communities. The chemical called hexavalent chromium, got public attention in the 2000 film “Erin Brockovich” and has been found to cause cancer in laboratory animals by the National Toxicology Program, part of the National Institutes of Health.

21 Dec 2010

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

Biovest International, Inc. today issued the following update in the form of a "Frequently Asked Questions" report in response to the high volume of inquiries received following the Company's recent presentation at the 2010 American Society of Hematology Annual Meeting (ASH 2010) in Orlando, Florida.

21 Dec 2010

BioInvent, Japanese pharmaceutical extends partnership for therapeutic candidate development

BioInvent International AB today announced that it has signed an agreement to extend its existing collaboration with an undisclosed Japanese pharmaceutical group.

21 Dec 2010

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.

21 Dec 2010

Royal DSM to acquire Martek for $1,087 million

Royal DSM N.V., the global Life Sciences and Materials Sciences company, and Martek Biosciences Corporation today announce that they have entered into a definitive agreement under which DSM will acquire all the outstanding shares of common stock of Martek for US$31.50 in cash per share for total consideration of US$1,087 million.

21 Dec 2010

Biogen Idec acquires Neurimmune subsidiary

Biogen Idec and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43.

21 Dec 2010

Arrowhead launches new company, Ablaris to commercialize novel weight loss technology

Arrowhead Research Corporation today announced that it has executed an exclusive world-wide license on technology developed by Drs. Wadih Arap and Renata Pasqualini at MD Anderson Cancer Center for use in weight loss and obesity-related metabolic conditions, and that it has launched a new company, Ablaris Therapeutics Inc., to commercialize this platform.

20 Dec 2010

New communication toolkit could improve information and advice on emerging food risks

Improvements in the delivery of information and advice on emerging food risks could lead to fewer food-related illnesses, a reduction in economic losses related to food scares, and improved consumer confidence in foods.

20 Dec 2010

Patheon fourth quarter revenues increase 0.9% to $177.7 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today its results for the fourth quarter and full year ended October 31, 2010. Revenues for the fourth quarter were $177.7 million or 0.9 percent higher than the same period last year. Excluding currency fluctuations, current year fourth quarter revenues would have increased by approximately 5.0 percent versus the same period last year.

17 Dec 2010

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

Novavax, Inc. announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S. Food and Drug Administration (FDA) and is no longer on clinical hold. In November, the company reported that it had received a question from the FDA regarding chemistry, manufacturing and controls (CMC) that has now been resolved.

16 Dec 2010

Akonni receives $150,000 Phase I NSF grant to assess feasibility of developing lab-on-a-film microarray device

Akonni Biosystems, a molecular diagnostics company that develops, manufactures, and plans to market sophisticated molecular testing devices for diagnosing infectious diseases and human genetic disorders, announced today the receipt of a $150,000 Phase I Grant from the National Science Foundation (NSF). This initial round of funding from NSF will enable Akonni to assess the feasibility of developing a lab-on-a-film microarray device that can be manufactured in a reel-to-reel format.

16 Dec 2010

Almac recognised with 'News Flow of the Year' award

The Almac Group, one of the world's leading contract drug development and manufacturing organisations, was presented with the "News Flow of the Year" accolade at the 2010 Genesis Awards annual Gala dinner in London last week, following the company being shortlisted as a finalist in the category nominations. Now into its tenth year, Genesis is established as a leading life science networking conference.

16 Dec 2010

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Amoy Diagnostics announced today that its EGFR and BRAF mutation detection kits received market approval from China's State Food and Drug Administration (SFDA). The SFDA is the competent authority for regulating drugs and in vitro diagnostics in mainland China. The approval allows AmoyDx to market the EGFR and BRAF tests for clinical use in China.

15 Dec 2010